Vukelja, Svetislava J.

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study

O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., et al. (2021) · European Journal of Cancer

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 83

Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).

Osborne, C. R. C., O'Shaughnessy, J., Holmes, F. A., Kim, H. S., Kocs, D. M., Steinberg, M. S., Richards, P. D., Vukelja, S. J., Berkowitz, N. C., & Buchbinder, A. (2012) · Journal of Clinical Oncology

Cancer Treatment and PharmacologyCancer therapeutics and mechanisms

Cited by 10